Form 4: Coeptis Therapeutics Director Gene Salkind Receives Stock Option Grant

Sentiment:

SEC Form 4 Filing


Director Gene Salkind received a grant of 5,700 non-qualified stock options from Coeptis Therapeutics Holdings, Inc. on March 4, 2025.

Summary

  • Gene Salkind, a director of Coeptis Therapeutics Holdings, Inc., received a grant of 5,700 non-qualified stock options on March 4, 2025.
  • The options were granted under the company's 2022 equity incentive plan.
  • The exercise price of the options is $10.56, which is equal to the company's stock price on the Nasdaq Capital Market on the day of the grant.
  • The options will vest over one year in four equal installments, with 25% vesting on March 31, 2025, June 30, 2025, September 30, 2025, and December 31, 2025.
  • The expiration date of the options is ten years from the grant date.

Sentiment

Score: 7

Explanation: The document indicates a standard compensation practice, suggesting stability and alignment of interests. It's a neutral-positive event.

Positives

  • The grant of stock options aligns the director's interests with those of the shareholders.
  • The vesting schedule incentivizes the director to remain with the company for at least one year.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock price.

Comparison to Industry Standards

  • Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
  • The vesting schedule of one year with quarterly installments is fairly typical.
  • The exercise price being set at the fair market value (FMV) on the grant date is also standard practice.

Stakeholder Impact

  • Shareholders may view the stock option grant positively as it aligns the director's interests with increasing shareholder value.
  • The director is incentivized to contribute to the company's success to realize the value of the options.

Key Dates

DateDescription
03/04/2025Date of stock option grant
03/31/2025First vesting date (25%)
06/30/2025Second vesting date (25%)
09/30/2025Third vesting date (25%)
12/31/2025Final vesting date (25%)
03/06/2025Date of Form 4 filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.